GPATGP-Act III Acquisition Corp.(GPAT)Stock Analysis

AI analysis on 2,800+ stocks →
FinancialsNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1834526GPAT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GPAT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GP-Act III Acquisition Corp. (GPAT), a Financials sector company. GPAT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), GP-Act III Acquisition Corp. reports net income of $2.2M, free cash flow of $-108.2K. Top institutional holders of GPAT by reported 13-F value include Karpus Management,, First Capital Management L.P., Alberta Investment Management, based on the most recent SEC filings. GPAT trades on the Nasdaq exchange and files with the SEC under CIK 1834526. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GPAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GP-Act III Acquisition Corp. directly from SEC EDGAR.

Net Income

Q1 2026

$2.2M

Free Cash Flow

Q1 2026

$-108.2K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+84792.4% YoY
$11.9MFY 2025
FY23 $-14.0KFY25 $11.9M

Operating Income

-3830.8% YoY
$-551.9KFY 2025
FY23 $-14.0KFY25 $-551.9K

Total Assets

+58245.2% YoY
$309.4MFY 2025
FY23 $530.2KFY25 $309.4M

Op. Cash Flow

-3293.1% YoY
$-372.2KFY 2025
FY23 $-11.0KFY25 $-372.2K

AI Insight: GPAT Financial Trends

GPAT shows stagnant profitability with deteriorating equity and negative operating income persistence.

Net income stabilized at $3M per quarter from Q3 2024 through Q3 2025, then declined to $2M in Q1 2026.

Operating income remains negative, worsening to -$1M in Q1 2026 from -$0M in prior quarters.

Operating cash flow flat-to-negative across all eight quarters, showing no cash generation improvement.

Equity deteriorated from -$14M to -$15M in Q1 2026, signaling balance-sheet stress and negative book value.

Operating loss acceleration in Q1 2026 marks first material decline in op income; monitor for further erosion.

AI Insight: GPAT Ratio Trends

Asset returns have deteriorated sharply to 2.8% ROA in Q1 2026, the lowest in the dataset, signaling weakening operational efficiency.

ROA declined from 3.7% in Q4 2025 to 2.8% in Q1 2026, marking the lowest quarterly return on assets in the nine-quarter history.

TTM ROA stands at 3.6%, below the Q3 2024 peak of 5.0%, indicating sustained pressure on asset productivity over the past 18 months.

Q1 2026 ROA collapse to 2.8% warrants investigation into one-time charges, seasonal patterns, or structural asset quality deterioration.

Limited data on profitability metrics (OpMargin, NPM, ROE, ROIC, D/E all absent) restricts full-picture assessment of financial health.

Get alerted when GPAT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GP-Act III Acquisition Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of GPAT

Put GPAT on your watchlist

Track score changes the day GP-Act III Acquisition Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is GPAT a good stock to buy?

13F Pro's AI-powered analysis of GP-Act III Acquisition Corp. (GPAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GPAT are available on the GPAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GPAT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GPAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GP-Act III Acquisition Corp.'s investment landscape.